Dubaere E, et al. - Researchers retrospectively analyzed data of 189 patients treated with stereotactic ablative body radiotherapy (SABR) with curative intent for non-small cell lung cancer (NSCLC) cancer to determine their outcomes regarding local, regional and distant tumor control, disease-free survival (DFS), overall survival (OS) and toxicity. Outcomes revealed the 2 and 4-year OS and DFS rates of 65% and 37%, respectively and 49% and 31%, respectively. The cumulative incidence function of local relapses, regional relapses and distant relapses at 2 and 4 years were 15% and 18%, 10% and 12%, 15% and 20%, respectively. At 2 and 4 years, the cumulative incidence function of any relapses were 28 and 34%, respectively. Findings suggest that SABR for peripheral stage I NSCLC led to long-term local control and survival in this large series of patients with the expected low toxicity.